.Structure Therapeutics
-
.Structure Therapeutics to Release ACCESS Clinical Program Data for Oral Small‑Molecule GLP‑1 Agonist Aleniglipron on Dec 8, 2025
words.Structure Therapeutics (NASDAQ: GPCR) will announce topline results from its ACCESS trial of alenigilprion, an oral GLP‑1 receptor agonist for obesity, before market open on Monday, Dec 8 2025. Management will discuss the data in a conference call and webcast at 8:30 a.m. ET, with a replay posted two hours later and available for 90 days. The release follows previous catalyst‑driven updates and aligns with the company’s cash‑rich outlook and ongoing oral‑therapy strategy.
